JP2022153405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022153405A5 JP2022153405A5 JP2022107980A JP2022107980A JP2022153405A5 JP 2022153405 A5 JP2022153405 A5 JP 2022153405A5 JP 2022107980 A JP2022107980 A JP 2022107980A JP 2022107980 A JP2022107980 A JP 2022107980A JP 2022153405 A5 JP2022153405 A5 JP 2022153405A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- seq
- monovalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024095141A JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762452187P | 2017-01-30 | 2017-01-30 | |
| US62/452,187 | 2017-01-30 | ||
| JP2019538396A JP7101684B2 (ja) | 2017-01-30 | 2018-01-30 | 一価の抗プロペルジン抗体および抗体断片 |
| PCT/US2018/015985 WO2018140956A1 (en) | 2017-01-30 | 2018-01-30 | Monovalent anti-properdin antibodies and antibody fragments |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538396A Division JP7101684B2 (ja) | 2017-01-30 | 2018-01-30 | 一価の抗プロペルジン抗体および抗体断片 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024095141A Division JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022153405A JP2022153405A (ja) | 2022-10-12 |
| JP2022153405A5 true JP2022153405A5 (https=) | 2023-04-26 |
Family
ID=62978808
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538396A Active JP7101684B2 (ja) | 2017-01-30 | 2018-01-30 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2022107980A Pending JP2022153405A (ja) | 2017-01-30 | 2022-07-04 | 一価の抗プロペルジン抗体および抗体断片 |
| JP2024095141A Pending JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538396A Active JP7101684B2 (ja) | 2017-01-30 | 2018-01-30 | 一価の抗プロペルジン抗体および抗体断片 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024095141A Pending JP2024116321A (ja) | 2017-01-30 | 2024-06-12 | 一価の抗プロペルジン抗体および抗体断片 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11198725B2 (https=) |
| EP (1) | EP3573661A4 (https=) |
| JP (3) | JP7101684B2 (https=) |
| KR (2) | KR102613874B1 (https=) |
| CN (2) | CN110831626B (https=) |
| AU (2) | AU2018212012B2 (https=) |
| BR (1) | BR112019014652A2 (https=) |
| CA (1) | CA3049806A1 (https=) |
| CO (1) | CO2019007686A2 (https=) |
| IL (2) | IL267898B2 (https=) |
| MX (3) | MX2019008827A (https=) |
| WO (1) | WO2018140956A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019008827A (es) * | 2017-01-30 | 2019-09-26 | Alexion Pharma Inc | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. |
| KR102806328B1 (ko) * | 2017-07-11 | 2025-05-14 | 알렉시온 파마슈티칼스, 인코포레이티드 | 보체 성분 c5 또는 혈청 알부민에 결합하는 폴리펩티드 및 그의 융합 단백질 |
| JP7222075B2 (ja) * | 2018-09-13 | 2023-02-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット |
| US12570732B2 (en) | 2020-01-08 | 2026-03-10 | Zydus Lifesciences Limited | Anti-properdin antibodies and preparation thereof |
| CN116437913A (zh) | 2020-09-23 | 2023-07-14 | 艾其林医药公司 | 用于治疗补体介导的病症的药物化合物 |
| CN118436786A (zh) * | 2020-10-30 | 2024-08-06 | 广州市妇女儿童医疗中心 | 诊治胆道闭锁的方法 |
| WO2023023227A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors |
| US11981727B2 (en) | 2021-08-31 | 2024-05-14 | Novelmed Therapeutics, Inc | Monospecific and bispecific antibodies and antigen binding fragments thereof |
| WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
| CA3264087A1 (en) * | 2022-08-05 | 2024-02-08 | Alexion Pharmaceuticals, Inc. | Pharmaceutical compositions based on fusion proteins and their methods of use |
| CN120018862A (zh) * | 2022-08-31 | 2025-05-16 | 阿雷克森制药公司 | 用于治疗镰状细胞病的融合多肽的剂量和施用 |
| KR20250112858A (ko) | 2022-11-25 | 2025-07-24 | 리노 파마슈티컬스 아이엔씨. | 프로퍼딘 결합 단백질 및 이의 용도 |
| CN120399074B (zh) * | 2023-06-02 | 2025-12-30 | 安徽金百奥生物科技有限公司 | 一种与人dr3胞外域高亲和力的纳米抗体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| US7423128B2 (en) | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
| BRPI0606934A2 (pt) | 2005-01-25 | 2017-07-11 | Cell Therapeutics Inc | Conjugado de proteína biologicamente ativa, composição, molécula de dna quimérica, vetor, célula, e, métodos para preparar conjugado de proteína biologicamente ativa, e para determinar se um dado conjugado de proteína exibe uma meia-vida de plasma modificada comparada com a meia-vida intrínseca do polipeptídeo biologicamente ativo não conjungado |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| SG10201804008UA (en) * | 2005-11-04 | 2018-06-28 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| DK2262831T3 (en) * | 2008-03-03 | 2015-04-27 | Novelmed Therapeutics Inc | ANTI-Properdin ANTIBODIES |
| CA2766565A1 (en) | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Bispecific antibodies that bind to complement proteins |
| US20110172398A1 (en) | 2009-10-02 | 2011-07-14 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules for anti-angiogenesis therapy |
| CA2811221C (en) * | 2010-03-10 | 2018-01-09 | Novelmed Therapeutics, Inc. | Humanized and chimeric anti-properdin antibodies |
| PT2621515T (pt) | 2010-09-28 | 2017-07-12 | Aegerion Pharmaceuticals Inc | Polipéptido quimérico de leptina de foca-ser humano com solubilidade aumentada |
| AU2011328246B2 (en) | 2010-11-08 | 2016-06-30 | Ablynx N.V. | CXCR2 binding polypeptides |
| KR20140064768A (ko) | 2011-07-01 | 2014-05-28 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 항-프로퍼딘 항체 및 그의 용도 |
| JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
| ES2728278T3 (es) * | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
| WO2013102123A2 (en) | 2011-12-28 | 2013-07-04 | Novelmed Therapeutics, Inc. | Aglycosylated human antibody and fusion protein and uses thereof |
| CA2887050A1 (en) | 2012-10-04 | 2014-04-10 | Novelmed Therapeutics, Inc. | Alternative pathway specific antibodies for treating hemolytic diseases |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| MX2019008827A (es) * | 2017-01-30 | 2019-09-26 | Alexion Pharma Inc | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. |
| CN110003335B (zh) * | 2019-04-12 | 2023-07-04 | 深圳普瑞金生物药业股份有限公司 | Cd47单域抗体、核酸及试剂盒 |
-
2018
- 2018-01-30 MX MX2019008827A patent/MX2019008827A/es unknown
- 2018-01-30 IL IL267898A patent/IL267898B2/en unknown
- 2018-01-30 KR KR1020197021910A patent/KR102613874B1/ko active Active
- 2018-01-30 BR BR112019014652-0A patent/BR112019014652A2/pt active Search and Examination
- 2018-01-30 EP EP18744926.9A patent/EP3573661A4/en active Pending
- 2018-01-30 KR KR1020237042534A patent/KR20230173731A/ko not_active Ceased
- 2018-01-30 CN CN201880008892.6A patent/CN110831626B/zh active Active
- 2018-01-30 WO PCT/US2018/015985 patent/WO2018140956A1/en not_active Ceased
- 2018-01-30 US US16/479,335 patent/US11198725B2/en active Active
- 2018-01-30 JP JP2019538396A patent/JP7101684B2/ja active Active
- 2018-01-30 CA CA3049806A patent/CA3049806A1/en active Pending
- 2018-01-30 CN CN202410325026.7A patent/CN118184777A/zh active Pending
- 2018-01-30 AU AU2018212012A patent/AU2018212012B2/en active Active
- 2018-01-30 IL IL309890A patent/IL309890A/en unknown
-
2019
- 2019-07-17 CO CONC2019/0007686A patent/CO2019007686A2/es unknown
- 2019-07-25 MX MX2023007840A patent/MX2023007840A/es unknown
- 2019-07-25 MX MX2023004333A patent/MX2023004333A/es unknown
-
2021
- 2021-11-09 US US17/522,028 patent/US12497445B2/en active Active
-
2022
- 2022-07-04 JP JP2022107980A patent/JP2022153405A/ja active Pending
-
2024
- 2024-06-12 JP JP2024095141A patent/JP2024116321A/ja active Pending
-
2025
- 2025-02-03 AU AU2025200709A patent/AU2025200709A1/en active Pending
- 2025-11-13 US US19/387,895 patent/US20260070963A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022153405A5 (https=) | ||
| JP2024116321A5 (https=) | ||
| JP2020507561A5 (https=) | ||
| Davis et al. | Serum IgA Fc effector functions in infectious disease and cancer | |
| US11192941B2 (en) | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof | |
| AU2015265624B2 (en) | Combination of lenalidomide or pomalidomide and CD38 antibody-attenuated interferon-alpha constructs, and the use thereof | |
| Ricklin et al. | Complement in immune and inflammatory disorders: pathophysiological mechanisms | |
| AU2016354117B2 (en) | Methods for treating conditions associated with MASP-2 dependent complement activation | |
| JP2755395B2 (ja) | Ｈｉｖ感染細胞に殺作用する抗体異種結合体 | |
| AU2014337047B2 (en) | Methods for treating conditions associated with MASP-2 dependent complement activation | |
| RU2687588C2 (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| JP2022084623A (ja) | 組織因子経路インヒビター抗体およびその使用 | |
| Bates et al. | Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein | |
| JP2019535763A5 (https=) | ||
| Pires et al. | Hyper‐inflammation and complement in COVID‐19 | |
| JP2023116479A5 (https=) | ||
| JP2008538564A5 (https=) | ||
| AU2018318982A2 (en) | Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant | |
| JP2019505527A5 (https=) | ||
| JP2019527543A5 (https=) | ||
| US20220267415A1 (en) | Multimeric sars-cov-2 binding molecules and uses thereof | |
| KR20150031298A (ko) | 다양한 질환 및 장애의 치료를 위해 masp-1 및/또는 masp-2 및/또는 masp-3를 억제하는 조성물 및 방법 | |
| MXPA05013789A (es) | Composiciones y metodos para tratar los desordenes relacionados con la coagulacion. | |
| Sroga et al. | Nanobodies: a new approach for the diagnosis and treatment of viral infectious diseases | |
| JP2017534296A5 (https=) |